Pay in 4 interest-free payments of $5.98 Learn more
Ships within 48 hours · Estimated delivery Aug 10 - Aug 15
The results paved the way for liraglutide, branded as Saxenda, to be approved in the US as a once-a-day subcutaneous injection in December 2014 and in Europe in 2015 for the treatment of chronic weight management combined with a reduced calorie diet and increased physical exercise (Molteni, Chen)
R.DawsonG.et al (2010)
A research guide to the component mechanisms and the co-administration rationale
10.1085/jgp.201611637 32
Some countries have banned this product because of a potential connection to the development of cancer
US$ 28.06
US$ 21.94
US$ 22.74
US$ 27.71
